Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

60 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Ruxolitinib is more effective than other JAK inhibitors to treat VEXAS syndrome: a retrospective multicenter study.
Heiblig M, Ferrada MA, Koster MJ, Barba T, Gerfaud-Valentin M, Mékinian A, Coelho H, Fossard G, Barraco F, Galicier L, Bienvenu B, Hirsch P, Vial G, Boutin AB, Galland J, Le Guenno G, Bigot A, Warrington KJ, Kermani TA, Grayson PC, Patel BA, Beck DB, Jamilloux Y, Fenaux P, Sujobert P. Heiblig M, et al. Among authors: barraco f. Blood. 2022 Aug 25;140(8):927-931. doi: 10.1182/blood.2022016642. Blood. 2022. PMID: 35609174 Free PMC article.
Treatment with Low-Dose Cytarabine in Elderly Patients (Age 70 Years or Older) with Acute Myeloid Leukemia: A Single Institution Experience.
Heiblig M, Elhamri M, Tigaud I, Plesa A, Barraco F, Labussière H, Ducastelle S, Michallet M, Nicolini F, Plesa C, Wattel E, Salles G, Thomas X. Heiblig M, et al. Among authors: barraco f. Mediterr J Hematol Infect Dis. 2016 Jan 1;8(1):e2016009. doi: 10.4084/MJHID.2016.009. eCollection 2016. Mediterr J Hematol Infect Dis. 2016. PMID: 26740870 Free PMC article.
Treatment patterns and comparative effectiveness in elderly acute myeloid leukemia patients (age 70 years or older): the Lyon-university hospital experience.
Heiblig M, Le Jeune C, Elhamri M, Balsat M, Tigaud I, Plesa A, Barraco F, Labussière H, Ducastelle S, Nicolini F, Wattel E, Salles G, Thomas X. Heiblig M, et al. Among authors: barraco f. Leuk Lymphoma. 2017 Jan;58(1):110-117. doi: 10.1080/10428194.2016.1180688. Epub 2016 May 17. Leuk Lymphoma. 2017. PMID: 27184036
Elderly Patients (Age 70 Years or Older) With Secondary Acute Myeloid Leukemia or Acute Myeloid Leukemia Developed Concurrently to Another Malignant Disease.
Collinge E, Loron S, Larcher MV, Elhamri M, Heiblig M, Deloire A, Ducastelle S, Labussière H, Barraco F, Wattel E, Salles G, Paubelle E, Thomas X. Collinge E, et al. Among authors: barraco f. Clin Lymphoma Myeloma Leuk. 2018 May;18(5):e211-e218. doi: 10.1016/j.clml.2018.02.018. Epub 2018 Mar 2. Clin Lymphoma Myeloma Leuk. 2018. PMID: 29572159
Prognostic Value of Genetic Alterations in Elderly Patients with Acute Myeloid Leukemia: A Single Institution Experience.
Heiblig M, Labussière-Wallet H, Nicolini FE, Michallet M, Hayette S, Sujobert P, Plesa A, Balsat M, Paubelle E, Barraco F, Tigaud I, Ducastelle S, Wattel E, Salles G, Thomas X. Heiblig M, et al. Among authors: barraco f. Cancers (Basel). 2019 Apr 22;11(4):570. doi: 10.3390/cancers11040570. Cancers (Basel). 2019. PMID: 31013658 Free PMC article.
Lyon-University Hospital Experience with Gemtuzumab Ozogamicin Therapy in Acute Myeloid Leukemia: a 'Real-Life' Study.
Laurino M, Loron S, Larcher MV, Fossard G, Elhamri M, Deloire A, Balsat M, Barraco F, Labussière H, Ducastelle S, Renault M, Wattel E, Heiblig M, Salles G, Thomas X. Laurino M, et al. Among authors: barraco f. Mediterr J Hematol Infect Dis. 2020 May 1;12(1):e2020020. doi: 10.4084/MJHID.2020.020. eCollection 2020. Mediterr J Hematol Infect Dis. 2020. PMID: 32395209 Free PMC article.
Therapeutic options in VEXAS syndrome: insights from a retrospective series.
Bourbon E, Heiblig M, Gerfaud Valentin M, Barba T, Durel CA, Lega JC, Barraco F, Sève P, Jamilloux Y, Sujobert P. Bourbon E, et al. Among authors: barraco f. Blood. 2021 Jul 1;137(26):3682-3684. doi: 10.1182/blood.2020010177. Blood. 2021. PMID: 33619558 Free article. Review. No abstract available.
The Impact of DNMT3A Status on NPM1 MRD Predictive Value and Survival in Elderly AML Patients Treated Intensively.
Heiblig M, Duployez N, Marceau A, Lebon D, Goursaud L, Plantier I, Stalnikiewich L, Cambier N, Balsat M, Fossard G, Labussière-Wallet H, Barraco F, Ducastelle-Lepretre S, Sujobert P, Huet S, Hayette S, Ghesquières H, Thomas X, Preudhomme C. Heiblig M, et al. Among authors: barraco f. Cancers (Basel). 2021 Apr 29;13(9):2156. doi: 10.3390/cancers13092156. Cancers (Basel). 2021. PMID: 33947035 Free PMC article.
Measurable residual disease including AML leukemia stem cell flow evaluation of CPX-351 therapy by multi-parameter flow cytometry.
Plesa A, Roumier C, Gutrin J, Larcher MV, Balsat M, Cadassou O, Barraco F, Fossard G, Baudouin A, Labussière H, Tigaud I, Ducastelle S, Hayette S, Sujobert P, Heiblig M, Elhamri M, Thomas X. Plesa A, et al. Among authors: barraco f. Leuk Res. 2021 Dec;111:106673. doi: 10.1016/j.leukres.2021.106673. Epub 2021 Jul 26. Leuk Res. 2021. PMID: 34364023 No abstract available.
Successful allogeneic hematopoietic stem cell transplantation in patients with VEXAS syndrome: a 2-center experience.
Diarra A, Duployez N, Fournier E, Preudhomme C, Coiteux V, Magro L, Quesnel B, Heiblig M, Sujobert P, Barraco F, Balsat M, Scanvion Q, Hachulla E, Launay D, Yakoub-Agha I, Terriou L. Diarra A, et al. Among authors: barraco f. Blood Adv. 2022 Feb 8;6(3):998-1003. doi: 10.1182/bloodadvances.2021004749. Blood Adv. 2022. PMID: 34714914 Free PMC article.
60 results